Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-10T20:29:50.517Z Has data issue: false hasContentIssue false
  • English
  • Français

Reducing psychotropic drug use in people with dementia living in nursing homes

Published online by Cambridge University Press:  20 March 2020

Clive Ballard  and
Anne Corbett
Clive Ballard*
Affiliation:
University of Exeter Medical School, Exeter, UK
Anne Corbett
Affiliation:
University of Exeter Medical School, Exeter, UK
*
Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
International Psychogeriatrics , Volume 32 , Issue 3: Issue Theme: Improving Healthcare in Long-Term Care and Nursing Homes , March 2020 , pp. 291 - 294
Copyright
© International Psychogeriatric Association 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aalten, P.et al. (2007). Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dementia and Geriatric Cognitive Disorders, 24, 457–463.10.1159/000110738CrossRefGoogle ScholarPubMed
American Psychiatric Association. (2007). Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Available at: http://psychiatryonline.org/content.aspx?bookid=28&sectionid=1679489; last accessed 18 August 2019.Google Scholar
Ballard, C.et al. (2016). Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the Well-Being and Health for People With Dementia (WHELD) Program. The American Journal of Psychiatry, 173, 252–262.10.1176/appi.ajp.2015.15010130CrossRefGoogle ScholarPubMed
Ballard, C.G., Eastwood, C., Gahir, M. and Wilcock, G (1996). A follow up study of depression in the carers of dementia sufferers. BMJ, 312, 947.10.1136/bmj.312.7036.947CrossRefGoogle ScholarPubMed
Banerjee, S. (2009). The use of antipsychotic medication for people with dementia: time for action…. A Report for the Department of Health (UK). Available at: http://psychrights.org/Research/Digest/NLPs/BanerjeeReportOnGeriatricNeurolepticUse.pdf; last accessed 4 September 2019.Google Scholar
Corbett, A., Smith, J., Creese, B. and Ballard, C. (2012). Treatment of behavioral and psychological symptoms of Alzheimer’s disease. Current Treatment Options in Neurology, 14, 113–125.10.1007/s11940-012-0166-9CrossRefGoogle ScholarPubMed
Coupland, C.A.C., Hill, T., Dening, T., Morriss, R., Moore, M. and Hippisley-Cox, J. (2019). Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Internal Medicine, 179, 1084–1093.10.1001/jamainternmed.2019.0677CrossRefGoogle Scholar
Erdal, A.et al. (2018). Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM). Clinical Interventions in Aging, 13, 935–946.10.2147/CIA.S161052CrossRefGoogle Scholar
Fleisher, A.S.et al. (2011). Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology, 77, 1263–1271.10.1212/WNL.0b013e318230a16cCrossRefGoogle ScholarPubMed
Fossey, J.et al. (2006). Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ, 332, 756–761.10.1136/bmj.38782.575868.7CCrossRefGoogle ScholarPubMed
Fox, C., Arthur, A. and Ballard, C. (2018). Beyond anti-psychotics: exploring efficacy and harms of Z-drugs for sleep disturbance on the progression of key dementia outcomes. Alzheimer’s Association International Conference, London.10.1016/j.jalz.2018.06.1378CrossRefGoogle Scholar
Gilley, D.W., Whalen, M.E., Wilson, R.S. and Bennett, D.A. (1991). Hallucinations and associated factors in Alzheimer’s disease. The Journal of Neuropsychiatry and Clinical Neurosciences, 3, 371–376.Google ScholarPubMed
Livingston, G.et al. (2017). Dementia prevention, intervention, and care. The Lancet, 390, 2673–2734.10.1016/S0140-6736(17)31363-6CrossRefGoogle ScholarPubMed
Lyketsos, C.G.et al. (2001). Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: the Cache County study. International Journal of Geriatric Psychiatry, 16, 1043–1053.10.1002/gps.448CrossRefGoogle ScholarPubMed
Maust, D.T.et al. (2015). Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry, 72, 438–445.10.1001/jamapsychiatry.2014.3018CrossRefGoogle ScholarPubMed
Medicines and Healthcare Products Regulatory Agency. (2014). Antipsychotics: initiative to reduce prescribing to older people with dementia. Available at: https://www.gov.uk/drug-safety-update/antipsychotics-initiative-to-reduce-prescribing-to-older-people-with-dementia; last accessed 4 September 2019.Google Scholar
Muñiz, R.et al. (2019). The “CHROME criteria”: tool to optimize and audit prescription quality of psychotropic medications in institutionalized people with dementia. International Psychogeriatrics, 32, 315–324.10.1017/S104161021900111XCrossRefGoogle ScholarPubMed
Porsteinsson, A.P.et al. (2014). Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA: The Journal of the American Medical Association, 311, 682–691.10.1001/jama.2014.93CrossRefGoogle ScholarPubMed
Scarmeas, N.et al. (2005) Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Archives of Neurology, 62, 1601–1608.10.1001/archneur.62.10.1601CrossRefGoogle ScholarPubMed
Wadsworth, L.P.et al. (2012) Neuropsychiatric symptoms and global functional impairment along the Alzheimer’s continuum. Dementia and Geriatric Cognitive Disorders, 34, 96–111.10.1159/000342119CrossRefGoogle ScholarPubMed